-+ 0.00%
-+ 0.00%
-+ 0.00%

GENMAB TO SUBMIT SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) TO U.S. FOOD AND DRUG ADMINISTRATION FOR EPCORITAMAB PLUS RITUXIMAB AND LENALIDOMIDE (R2) IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL)

Reuters·05/02/2025 00:24:00

Please log in to view news